Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

mdma

  • Home
  •  
  • mdma



  • Most Read
  • Latest Comments
  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Tryptamine Therapeutics’ psilocybin trials deliver pain relief to all patients
    Tryptamine Therapeutics' psilocybin trials deliver pain relief to all patients
    • News

  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • News

  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    • News

  • TGA gives green light to Emyria’s psychiatrists for MDMA therapy for PTSD
    TGA gives green light to Emyria’s psychiatrists for MDMA therapy for PTSD
    • News

  • Vape imports banned, Vitura introduces nicotine vaping products to tap new market
    Vape imports banned, Vitura introduces nicotine vaping products to tap new market
    • News

  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    • News

    Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme

    In July last year, Australia became the first country to legalise ecstasy (MDMA) and magic mushrooms (psilocybin) for mental health disorders, including PTSD and depression. A bold move, it spurred medical businesses into action, seeking the proper approvals and getting the early advantage. At the same time, not all medical professionals were so thrilled, citing

    Read More
    Public
  • Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa
    • News

    Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa

    In May 2023, diversified digital health company Vitura Health (ASX: VIT) announced a joint venture with Canadian psychedelic company PharmAla Biotech, giving birth to its Melbourne-based psychedelics arm, Cortexa. Providing an update on the 50-50 venture, the Company has noted an “Australian first” win. Its MDMA bulk GMP (good manufacturing practice) Active Pharmaceutical Ingredient (API)

    Read More
    Public
  • Melodiol reports positive results from Halucenex trials for magic mushrooms to treat PTSD
    • News

    Melodiol reports positive results from Halucenex trials for magic mushrooms to treat PTSD

    In Australia, about 43% of people aged between 16 and 85 had experienced a mental disorder at some point as of 2023. Between 2021 and 2022, over 44 million mental health-related meds, largely anti-depressants, were dispensed. While traditional treatments are only about 20 to 30% effective in treating anxiety and depression, recreational cannabis company Melodiol

    Read More
    Public
  • Cann Group poised for growth as demand for locally produced cannabis surges
    • News

    Cann Group poised for growth as demand for locally produced cannabis surges

    Australia has made a groundbreaking decision by becoming the first country to legalise the clinical prescribing of MDMA (ecstasy) and psilocybin (magic mushrooms) for the treatment of specific mental health disorders, including PTSD and treatment-resistant depression. Setting Australia apart as the pioneer in adopting psychoactive-based treatments for mental health, as of 1 July, authorised psychiatrists

    Read More
    Public
  • Treating mental health; TGA approves MDMA and Psilocybin as a medicine
    • News

    Treating mental health; TGA approves MDMA and Psilocybin as a medicine

    Although it doesn’t apply to me, many of you may remember the early mornings during adolescence when you were throwing yourself around in a club, parading a locked-jaw, and beaming pupils so wide it would be hard to deny that you weren’t on something. Well, chances are, you had consumed MDMA, or if you were

    Read More
    Public
  • Does IP ownership of MDMA compounds reduce its potential for healthcare benefits?
    • Opinion

    Does IP ownership of MDMA compounds reduce its potential for healthcare benefits?

    If you read my articles often, you would know that I can become quite laudatory when discussing small cap companies excelling in recreational drug regulation and using once illegal drugs to treat various mental health conditions and illnesses. Ranging from cannabis to psychedelics, and now, MDMA. Most of my articles surrounding this area follow the

    Read More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.